NASDAQ:NVIV InVivo Therapeutics (NVIV) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.22▼$0.7952-Week Range N/AVolume1.89 million shsAverage Volume8.25 million shsMarket Capitalization$997,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisEarningsHeadlinesShort InterestTrendsStock AnalysisEarningsHeadlinesShort InterestTrends Get InVivo Therapeutics alerts: Email Address Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About InVivo Therapeutics Stock (NASDAQ:NVIV)InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. On February 1, 2024, InVivo Therapeutics Holdings Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with InVivo Therapeutics Corporation.Read More Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. NVIV Stock News HeadlinesMay 26, 2024 | finance.yahoo.comInVivo Therapeutics Holdings Co (NVIVQ)May 17, 2024 | investing.comInVivo Therapeutics Holdings Corp (NVIVQ)July 26, 2024 | Porter & Company (Ad)Obama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” March 28, 2024 | msn.comGut health supplements are everywhere – but which are the best ones for *you*?February 15, 2024 | cnn.comInVivo Therapeutics Holdings CorporationFebruary 14, 2024 | wsj.comInVivo Therapeutics Holdings Corp.February 13, 2024 | wsj.comFirm Retention Summary: InVivo Therapeutics HoldingsFebruary 7, 2024 | investing.comInVivo Therapeutics Holdings Corp (NVIV)July 26, 2024 | Porter & Company (Ad)Obama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” February 6, 2024 | bizjournals.comBob Langer-founded device-maker declares bankruptcyFebruary 6, 2024 | investorplace.comWhy Is InVivo Therapeutics (NVIV) Stock Up 61% Today?February 1, 2024 | marketwatch.comInVivo Therapeutics Shares Plumb New Depths After Bankruptcy FilingNovember 10, 2023 | morningstar.comInVivo Therapeutics Holdings Corp NVIVJune 22, 2023 | marketwatch.comSpinal Cord Trauma Treatment Market Analysis: Examining Trends and Forecasting Revenue Growth with an estimated CAGR 6.2% from 2023-2030May 1, 2023 | benzinga.comRing Therapeutics Strengthens Executive Team with Appointment of Christopher McNulty as Chief Financial Officer, Head of Corporate StrategyMarch 17, 2023 | finance.yahoo.comWhy InVivo Therapeutics Shares Are Plunging TodayMarch 10, 2023 | msn.comInVivo seeks longer-term control in Casino-Teract retail tie-upMarch 10, 2023 | msn.comWhy Barnes & Noble Education Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving PremarketSee More Headlines Receive NVIV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InVivo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2020Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NVIV CUSIPN/A CIK1292519 Webwww.invivotherapeutics.com Phone(617) 863-5500FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,490,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-75.04% Return on Assets-65.01% Debt Debt-to-Equity RatioN/A Current Ratio14.30 Quick Ratio14.30 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.48 per share Price / BookN/AMiscellaneous Outstanding Shares3,110,000Free Float3,029,000Market Cap$997,000.00 OptionableNot Optionable Beta0.65 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Richard M. Toselli M.D. (Age 66)President, CEO, Chief Medical Officer & Director Comp: $825.2kMr. Richard C. Christopher (Age 54)CFO & Treasurer Comp: $537.82kMs. Heather M. Hamel J.D. (Age 34)Chief Legal Officer & General Counsel Comp: $446.96kDr. Robert S. Langer Jr. (Age 75)Ph.D., Co-Founder & Member of Scientific Advisory Board Dr. Joseph Philip Vacanti M.D. (Age 75)Co-Founder Key CompetitorsRa Medical SystemsNYSE:RMEDVenus ConceptNASDAQ:VEROSharps TechnologyNASDAQ:STSSSintx TechnologiesNASDAQ:SINTAvingerNASDAQ:AVGRView All Competitors NVIV Stock Analysis - Frequently Asked Questions How were InVivo Therapeutics' earnings last quarter? InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) posted its quarterly earnings data on Wednesday, May, 13th. The biotechnology company reported ($61.75) EPS for the quarter. When did InVivo Therapeutics' stock split? InVivo Therapeutics shares reverse split on Wednesday, April 27th 2022. The 1-25 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of InVivo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that InVivo Therapeutics investors own include Anavex Life Sciences (AVXL), Gilead Sciences (GILD), iShares Preferred and Income Securities ETF (PFF), Verastem (VSTM), Flexion Therapeutics (FLXN), Inovio Pharmaceuticals (INO) and Apollo Investment (AINV). This page (NASDAQ:NVIV) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InVivo Therapeutics Holdings Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share InVivo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.